All updates
All updates
today 46文献与产业新闻评分2525 顶刊论文（社媒热度）评分4141 Global access to different classes of diabetes medicines: a framework for targeted policy actions.
顶刊论文（社媒热度）评分3737 Psoriasis.
顶刊论文（社媒热度）评分3737 Beyond BCL-2: What drives venetoclax resistance in acute myeloid leukemia?
文献与产业新闻评分3838 Similar regulatory clocks, divergent paths to study start
文献与产业新闻评分2424 STAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and more
文献与产业新闻评分2424 STAT+: Are cancer patients getting too much drug?
文献与产业新闻评分4040 Loosening the reins: The bold risks required to overhaul first-in-human trials
文献与产业新闻评分3636 Opinion: A cure for HIV would be a triumph. But it shouldn’t harm survivors
文献与产业新闻评分2121 Opinion: Lil Nas X’s bipolar diagnosis and the paradox of treatment
文献与产业新闻评分4545 Focal therapy for localized prostate cancer has divided physicians. Will new data change minds?
顶刊论文（社媒热度）评分3737 The trials of translating psilocybin treatment from research to practice.
顶刊论文（社媒热度）评分4040 Putting epigenetic aging clocks on trial.
顶刊论文（社媒热度）评分3737 Can traditional medicines go mainstream?
文献与产业新闻评分4040 The trials of translating psilocybin treatment from research to practice
文献与产业新闻评分3636 Can traditional medicines go mainstream?
文献与产业新闻评分2929 Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review)
文献与产业新闻评分3232 Harnessing trained immunity for next-generation vaccines: from rational adjuvant design to self-adjuvanting antigens
文献与产业新闻评分2727 Molecular classification and precision therapy in gastric cancer: Current advances and future perspectives (Review)
顶刊论文（社媒热度）评分3939 Regulation of inflammation by oxidized lipids.
文献与产业新闻评分5656 Mapping first steps toward scaling genetic medicines: C-Path’s Romero on the BioCentury Show
文献与产业新闻评分4040 Big ambitions, big fractures — Europe’s FIH conundrum: Back to School 2026
文献与产业新闻评分2626 STAT+: One of the most consequential years for cancer treatment, ever
文献与产业新闻评分3333 STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
文献与产业新闻评分3030 Why Pheast’s CEO has no regrets about transparent approach to R&D despite competitors circling
文献与产业新闻评分3737 Reduce protein to increase longevity? Nutrition experts say that’s a bad idea
文献与产业新闻评分2222 Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
文献与产业新闻评分4545 Can reclassifying muscle dysmorphia unlock better care for boys and men?
顶刊论文（社媒热度）评分3636 Gastroparesis: A Review.
文献与产业新闻评分2929 Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013-2025
文献与产业新闻评分3535 The origin of non-specific effects of vaccines and the role of randomised clinical trials
文献与产业新闻评分4040 Outside of China, other Asian biotech hubs have early ambitions, too
文献与产业新闻评分4040 Trust in science: A new STAT initiative
文献与产业新闻评分4444 Australia looks beyond healthy volunteers to defend Phase I edge: Back to School 2026
顶刊论文（社媒热度）评分2222 Waking from the nightmare of PTSD.
文献与产业新闻评分3131 STAT+: What Epic did — and didn’t — say about AI at its annual meeting
文献与产业新闻评分99 New Biotech-Academia Partnership Approaches to Empower the Drug Development Ecosystem
文献与产业新闻评分1717 Developing a Global Clinical Trial Strategy for Emerging Biotechs
文献与产业新闻评分88 How Pharma Teams Evaluate Biotech Companies for Partnerships and Acquisitions
文献与产业新闻评分3535 Opinion: I’m a pediatrician. AI chatbots are grooming my patients